Peripheral Nerve Stimulators Market size was estimated over USD 541.2 million in 2024 and is estimated to reach USD 1.28 billion by the end of 2037, expanding at a CAGR of 7.5% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of peripheral nerve stimulators assessed at USD 581.7 million.
The rising number of patients suffering from chronic pain conditions, including neuropathy, back pain, and migraines, as well as neurological disorders such as stroke and spinal cord injuries, is significantly increasing the demand for effective pain management solutions and propelling peripheral nerve stimulators market. According to a WHO report released in March 2024, the incidence of diabetic neuropathy patients worldwide has tripled since 1990, reaching 206 million cases in 2021. Peripheral nerve stimulators (PNS) are gaining popularity due to their non-invasive nature, providing targeted relief by directly stimulating nerves and alleviating pain. Their ability to specifically address pain without the need for invasive surgery or medications makes them a preferred choice.
Additionally, the global movement away from opioid medications, driven by growing concerns about addiction, dependency, and severe side effects, is significantly increasing the demand for non-pharmacological therapies like peripheral nerve stimulators (PNS). These devices provide an effective and safer alternative for managing pain, offering targeted relief without the risks linked to opioid use. As a result, the adoption by patients and healthcare providers, seeking better pain management solutions is increasing. Thus, propelling the Peripheral Nerve stimulators market.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7.5% |
|
Base Year Market Size (2024) |
USD 541.2 million |
|
Forecast Year Market Size (2037) |
USD 1.28 billion |
|
Regional Scope |
|
Product Type (Transcutaneous, Implantable)
By product type, the transcutaneous segment is likely to dominate over 72.4% peripheral nerve stimulators market share by 2037. This segment in market is growing due to its non-invasive nature, offering a safer, more convenient alternative to surgical options. These cost-effective, easy-to-use devices are ideal for outpatient care, making them accessible to a broader patient base. Advancements in wearable technology and rising awareness of non-invasive pain management therapies are driving adoption. For instance, in September 2020, NeuroMetrix launched the Quell App for Apple Watch, a wearable TENS device for pain relief.
End user (Hospitals, Outpatient Centers)
Based on the end user, the outpatient segment is set to hold the majority of revenue share in the peripheral nerve stimulators market through the forecast period. The segment’s growth is attributed to the increasing demand for cost-effective and convenient treatment options. These centers offer quicker procedures and shorter recovery times compared to traditional hospital settings. Advancements in minimally invasive PNS technologies and the rising preference for outpatient care further drive growth in this segment. For instance, in August 2022, Minnetronix Medical’s MindsEye expandable brain access port, developed and FDA-cleared, was fully commercialized and distributed by Mizuho America in the U.S. Overall, propelling the market.
Our in-depth analysis of the global market includes the following segments:
|
Product Type |
|
|
End user |
|
North America Market Statistics
North America peripheral nerve stimulators market is predicted to hold revenue share of more than 39.2% by 2037. The opioid crisis in North America has pushed healthcare providers and policymakers to prioritize non-opioid pain management strategies. PNS devices offer a safer alternative for chronic pain management without the risk of addiction, thereby driving their adoption across the region. Chronic pain, driven by conditions such as arthritis and neuropathy, is widespread in North America, boosting demand for peripheral nerve stimulators as non-pharmacological treatment options. In 2021, an estimated 20.9% of U.S. adults (51.6 million people) had chronic pain, and 6.9% (17.1 million people) had high-impact chronic pain, according to CDC data published in 2023.
The U.S. is embarking on significant growth in the peripheral nerve stimulators market due to favorable reimbursement policies. The U.S. healthcare system has increasingly embraced restitution for peripheral nerve stimulators, encouraging their adoption. Comprehensive insurance coverage for these devices makes them accessible to a broader patient base, boosting market growth. Furthermore, key players are developing advanced, cost-efficient peripheral nerve stimulators, driving innovation, and expanding their applications within the U.S. healthcare systems.
Canada peripheral nerve stimulators market is growing due to advancements in neuromodulation, including wireless, minimally invasive, and patient-specific devices that enhance treatment and convenience. These innovations attract healthcare providers and patients, while educational efforts boost awareness and adoption. In July 2022, Abbott received Health Canada licensing for NeuroSphere Virtual Clinic, a remote programming technology. This first-of-its-kind solution improves access to treatment for chronic pain, Parkinson’s, and essential tremors, especially for patients facing travel challenges.
APAC Market Analysis
In Asia Pacific, the peripheral nerve stimulators market is set to hold notable market figures over the forecast period. Asia Pacific is home to one of the fastest-growing elderly populations. Age-related diseases, including neuropathy and spinal cord disorders, contribute to chronic pain, making PNS devices an attractive solution for improving the quality of life for older adults. Governments in the Asia Pacific are implementing favorable reimbursement policies for pain management treatment, including PNS devices, making these therapies more accessible and promoting market growth.
China is projected to register a remarkable adoption rate in the peripheral nerve stimulators market. China is becoming a hub for medical tourism, attracting patients seeking advanced pain management treatments. The increasing number of international patients opting for PNS therapy in China further supports market expansion. Large population in China with chronic pain and neurological disorders is driving demand for effective pain management solutions, such as peripheral nerve stimulators (PNS), boosting market growth.
There has been a notable increase in awareness about advanced pain management therapies in India. Patients and healthcare providers are becoming more familiar with the benefits of PNS as a safe, effective alternative to opioid-based pain relief, which is contributing to the market’s growth. Further, ongoing innovations are driving the adoption of PNS devices in India, especially in urban centers with advanced healthcare facilities. According to a PIB article, published in November 2024, the medical devices industry was estimated to grow from USD 14.0 billion (2024) to USD 30.0 billion (2030). Thus, propagating the market.
Key companies in the peripheral nerve stimulators market are driving innovation through advancements in technology, such as wireless, implantable, and programmable devices that enhance patient comfort and treatment efficacy. For instance, in June 2024, Nalu Medical announced key findings from a clinical trial evaluating the Nalu peripheral nerve stimulation system for treating chronic pain. Companies are developing compact, cost-effective PNS solutions with improved customization, integrating AI and remote monitoring to make therapy more accessible and personalized for chronic pain patients. These key players include:
Author Credits: Radhika Pawar
Copyright © 2025 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?